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Systemic corticosteroids play an integral role in the management of many inflammatory and immunologic
conditions, but these agents are also associated with serious risks. Osteoporosis, adrenal suppression,
hyperglycemia, dyslipidemia, cardiovascular disease, Cushing’s syndrome, psychiatric disturbances and
immunosuppression are among the more serious side effects noted with systemic corticosteroid therapy,
particularly when used at high doses for prolonged periods. This comprehensive article reviews these adverse
events and provides practical recommendations for their prevention and management based on both current
literature and the clinical experience of the authors.
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Since their discovery in the 1940s, corticosteroids have
become one of the most widely used and effective treat-
ments for various inflammatory and autoimmune disorders
(see Table 1). They are used as replacement therapy in
adrenal insufficiency (at physiologic doses) as well as in
supraphysiologic doses for the management of various
dermatologic, ophthalmologic, rheumatologic, pulmonary,
hematologic, and gastrointestinal (GI) disorders. In the field
of respirology, systemic corticosteroids are used for the
treatment of acute exacerbations of chronic obstructive
pulmonary disease (COPD) and severe, uncontrolled
asthma, as well as for inflammatory parenchymal lung
diseases such as hypersensitivity pneumonitis and immune-
mediated vasculitis. These are just some of the many
important uses of this group of medications that are utilized
in almost all areas of medicine.
Despite their beneficial effects, long-term systemic (oral
or parenteral) use of these agents is associated with well-
known adverse events (AEs) including: osteoporosis and* Correspondence: hlkimkw@gmail.com
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reproduction in any medium, provided the orfractures; adrenal suppression (AS); hyperglycemia and
diabetes; cardiovascular disease (CVD) and dyslipidemia,
dermatological and GI events; psychiatric disturbances;
and immunosuppression. The objectives of this article are
to: briefly review the properties and mechanisms of action
of systemic corticosteroids; discuss the AEs most com-
monly associated with long-term use of these agents; and
provide practical recommendations for patient monitoring
and the prevention and management of these AEs.Properties and mechanisms of action of
corticosteroids
Corticosteroids are synthetic analogues of the natural
steroid hormones produced by the adrenal cortex. Like
the natural hormones, these synthetic compounds have
glucocorticoid (GC) and/or mineralocorticoid properties.
Mineralocorticoids affect ion transport in the epithelial
cells of the renal tubules and are primarily involved in the
regulation of electrolyte and water balance. GCs, on the
other hand, are predominantly involved in carbohydrate,
fat and protein metabolism, and have anti-inflammatory,
immunosuppressive, anti-proliferative, and vasoconstrictive
effects (Table 2) [1].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Common clinical uses of systemic corticosteroids
Field of medicine Disorder(s)
Allergy and
respirology
• Moderate to severe asthma exacerbations










• Acute and chronic eosinophilic pneumonia
• Interstitial lung disease
Dermatology • Pemphigus vulgaris
• Acute, severe contact dermatitis
Endocrinology* • Adrenal insufficiency
• Congenital adrenal hyperplasia
















Other • Multiple sclerosis
• Organ transplantation
• Nephrotic syndrome
• Chronic active hepatitis
• Cerebral edema
NOTE: Systemic corticosteroid uses are not limited to those listed in this table.
These agents can be used in almost all areas of medicine.
*In endocrinology, corticosteroid doses are often given at or close to
physiologic doses rather than in therapeutic ranges.
Table 2 Primary effects of glucocorticoids (GCs) [1]
Anti-inflammatory: Inhibit inflammation by blocking the action of
inflammatory mediators (transrepression), or by
inducing anti-inflammatory mediators
(transactivation)
Immunosuppressive: Suppress delayed hypersensitivity reactions by
directly affecting T-lymphocytes
Anti-proliferative: Inhibition of DNA synthesis and epidermal cell
turnover
Vasoconstrictive: Inhibit the action of histamine and other
vasoconstrictive mediators
DNA deoxyribonucleic acid.
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actions of GCs are attributable, either directly or
indirectly, to their interaction with the cytosolic GC
receptor, which alters gene transcription to either induce
(transactivate) or repress (transrepress) gene transcrip-
tion in both inflammatory leukocytes and in structural
cells, such as epithelium [2-4]. Thus, GCs exert theirclinical effects predominantly by upregulating the
transcription of anti-inflammatory genes (transactivation)
or by downregulating the transcription of inflammatory
genes (transrepression) to affect the downstream pro-
duction of a number of pro-inflammatory cytokine
and chemokine proteins, cell adhesion molecules and other
key enzymes involved in the initiation and/or maintenance
of the host inflammatory response [3,5-7].
Systemic corticosteroids available in Canada
A number of systemic corticosteroid compounds are
commercially available in Canada. These agents differ
with respect to potency, duration of action and ratio of
mineralocorticoid to GC properties, which determine
the corticosteroid’s efficacy and therapeutic use (see
Table 3) [1,8].
Prednisone is perhaps the most widely used of the
systemic corticosteroids. Given its high GC activity
relative to mineralocorticoid activity, it is generally used
as an anti-inflammatory and immunosuppressive agent.
Although similar to prednisone and prednisolone,
methylprednisolone has even less mineralocorticoid
activity and, therefore, may be preferred when min-
eralocorticoid effects (e.g., water retention) are par-
ticularly undesirable [9]. Dexamethasone also has
minimal mineralocorticoid activity, but it is much
more potent and has a longer duration of action than
prednisone and prednisolone. Given its high potency,
long-term treatment with dexamethasone is associated
with severe hypothalamic-pituitary-adrenal (HPA) axis
suppression; therefore, it is generally reserved for
short-term use in very severe, acute conditions. Also,
its long duration of action makes it unsuitable for
alternate-day therapy [9].
Cortisone and hydrocortisone are the least potent
GCs. Because these agents have both mineralocorticoid
and GC activity, they are generally preferred for use in
patients with adrenal insufficiency. Fludrocortisone has
much greater mineralocorticoid vs. GC potency and,
therefore, is commonly used to replace aldosterone in
Addison's disease and the classic salt-wasting form of
congenital adrenal hyperplasia [1,8].

















Hydrocortisone 20 1 1 8-12 • Relatively high mineralocorticoid activity makes it
suitable for use in adrenal insufficiency
Cortisone 25 0.8 0.8 8-12 • Similar to hydrocortisone
Intermediate-acting
Prednisone 5 4 0.8 12-36 • High glucocorticoid activity makes it useful for long-
term treatment, and as an anti-inflammatory/
immunosuppressant
Prednisolone 5 4 0.8 12-36 • Similar to prednisone
Methylprednisolone 4 5 Minimal 12-36 • Anti-inflammatory/immunosuppressant
Triamcinolone 4 5 0 12-36 • Anti-inflammatory/immunosuppressant
Long-acting
Dexamethasone 0.75 30 Minimal 36-72 • Anti-inflammatory/immunosuppressant; used
especially when water retention is undesirable given its
minimal mineralocorticoid activity
• Usually reserved for short-term use in severe, acute
conditions given its high potency and long-duration of
action
Betamethasone 0.6 30 Negligible 36-72 • Similar to dexamethasone
Mineralocorticoids
Fludrocortisone ** 10-15 125-150 12-36 • Used for aldosterone replacement
Table adapted from NICE, 2012 [1]; Furst et al., 2012 [8].
*Equivalent dose shown is for oral or IV administration. Relative potency for intra-ocular or intramuscular administration may vary considerably.
**Glucocorticoid doses which provide a mineralocorticoid effect that is approximately equivalent to 0.1 mg of fludrocortisone are: prednisone or prednisolone
50 mg, or hydrocortisone 20 mg.
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events
A thorough review of corticosteroid dosing is beyond
the scope of this manuscript since dosages must be
individualized based on the pharmacokinetics of the
different preparations, the underlying condition being
treated, potential drug interactions with concurrently
administered non-steroid agents, and patient response
to GC treatment. In non-endocrine disorders, GCs are
commonly given in pharmacologic (therapeutic) doses to
suppress inflammation. In endocrine disorders, however,
corticosteroid doses are often given at or close to
physiologic doses (rather than in therapeutic ranges).
GC-associated toxicity appears to be related to both
the average dose and cumulative duration of GC use.
However, for most GC-related AEs, a “threshold” dose
or treatment duration has not been established [10]. The
following section provides a comprehensive review of
the most common AEs associated with long-term
systemic corticosteroid use.Adverse events associated with long-term
systemic corticosteroid use
Adults
The most common GC-associated AEs noted in adults in-
clude: osteoporosis and fractures; HPA-axis suppression;
Cushingoid appearance and weight gain; hyperglycemia/
diabetes; CVD and dyslipidemia; myopathy; cataracts and
glaucoma; psychiatric disturbances; immunosuppression;
as well as other GI and dermatologic events.
Osteoporosis, fractures and osteonecrosis
GCs have been shown to stimulate osteoclastic activity
initially (first 6–12 months of therapy), followed by a
decrease in bone formation by suppressing osteoblastic
activity in the bone marrow, decreasing osteoblast
function and life span, and promoting the apoptosis of
osteoblasts and osteocytes [11-13]. A meta-analysis
of over 80 studies in adults found that use of ≥5 mg/day
of prednisolone (or equivalent) was associated with
significant reductions in bone mineral density (BMD)
Table 4 Signs and symptoms of AS and adrenal crisis












• Poor linear growth in children
• Poor weight gain in children
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treatment initiation; this increased fracture risk was
independent of patient age, gender and the underlying
disease [14]. Kanis and colleagues examined 42,500
subjects from seven prospectively studied cohorts
followed for 176,000 patient-years and found that prior
and current use of corticosteroids increased fracture risk
in both adult men and women, regardless of BMD and
prior fracture history [15].
Osteonecrosis develops in 9–40% of adult patients
receiving long-term GC therapy; it can occur as a result
of systemic therapy or via intra-articular injections as
well as in the absence of GC-induced osteoporosis [16].
Osteonecrosis is also being increasingly reported in
children and adolescents treated for acute lymphoblastic
leukemia (ALL) and non-Hodgkin lymphoma [17,18].
Although the risk of osteonecrosis appears to increase
with higher doses and prolonged treatment, it may also
occur with low doses or after short-term GC exposure.
Excessive alcohol intake, hypercoaguable states, sickle
cell disease, radiation exposure and human immunodefi-
ciency virus (HIV) infection have also been associated
with the development of osteonecrosis [19].
A study of 270 adult cases of GC-induced osteonecro-
sis of the femoral head indicated that this condition was
often misdiagnosed as lumbar disorders [20]. In this
study, only one patient did not report any pain associ-
ated with osteonecrosis. Of the 269 patients who did
report symptoms, 79% experienced pain due to osteo-
necrosis within 3 years of GC initiation (median
18 months) [20].
Adrenal suppression
Adrenal suppression (AS) refers to decreased or inadequate
cortisol production that results from exposure of the HPA
axis to exogenous GCs [21]. Duration of GC therapy and
doses of GC treatment are not reliable predictors of which
patients will develop AS [22,23]. AS has been demonstrated
after exposure to even 5-days’ duration of high-dose GC
therapy [23]. It is important to recognize that inhaled,
topical and intraocular GCs may also be absorbed
systemically to the degree that they can cause AS [24-26].
Longer-acting GC formulations tend to be associated
with a higher risk of AS [27]. Timing of GC administra-
tion may also influence the development of AS, with
morning administration being potentially less suppressive
than evening doses [27,28]. Alternate-day therapy is also
theoretically less suppressive than daily GCs based on the
physiology of the HPA axis; however, there is currently no
solid clinical evidence to support this proposition.
The physiologic effects of cortisol are wide-ranging and
are particularly important during times of physiologic
stress (i.e., illness or surgery). The clinical presentation of
AS is variable; many of the signs and symptoms arenon-specific and can be mistaken for symptoms of
intercurrent illness or the underlying condition being
treated with GC therapy (see Table 4).
AS often occurs following abrupt discontinuation of
GC therapy [29]. However, there are currently no
evidence-based guidelines for tapering of GCs. Gradual
GC tapering is frequently part of treatment protocols to
reduce the risk of relapse and, therefore, comparative
studies looking at AS without tapering would be difficult
to perform. A study of patients with rheumatic disease
found that rapidity of steroid taper did not make a dif-
ference in HPA-axis recovery [30]. However, many of
these patients had undergone a gradual taper to prevent
disease relapse and were all on “close to” physiologic
doses of GC at the time of testing. In a study of children
with ALL, GC tapering before discontinuation did not
lead to complete resolution of AS [31]. Despite the lack
of supportive evidence, many centres follow empiric
tapering regimes based on the knowledge that AS is
often seen following abrupt GC withdrawal.
Cushingoid appearance and weight gain
Prolonged corticosteroid therapy commonly causes weight
gain and redistribution of adipose tissue that result in
Cushingoid features (truncal obesity, facial adipose tissue
[i.e., moon face], and dorsocervical adipose tissue). A survey
of 2,167 long-term GC users (mean prednisone equivalent
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be the most common self-reported AE (70%) [32]. An
analysis of four prospective trials of GC use in patients
with rheumatoid arthritis found a 4 to 8% increase in
mean body weight with the use of 5–10 mg/day of
prednisone or equivalent for >2 years [10].
Cushingoid features may develop within the first two
months of GC therapy, and the risk of these complications
appears to be dependent on both the dose and duration of
treatment. One study evaluating the prevalence of
Cushingoid abnormalities in 88 patients initiating long-
term systemic corticosteroid therapy (initial daily dose
≥20 mg of prednisone or equivalent) found the cumulative
incidence rates of these abnormalities to be 61% at
3 months and almost 70% at 12 months [33]. The
risk of these complications was higher in younger
patients, those with a higher baseline body mass
index (BMI) and those with a higher initial caloric
intake (>30 kcal/kg/day). Another study found the
rate of Cushingoid features to increase linearly with
dose: 4.3%, 15.8%, and 24.6% in patients receiving
<5 mg/day, 5–7.5 mg/day, and >7.5 mg/day of
prednisone (or equivalent), respectively [34].Hyperglycemia and diabetes
Exogenous corticosteroid use is associated with hyper-
glycemia, and high-dose therapy increases insulin resist-
ance in patients with pre-existing and new-onset diabetes.
The effects of GC administration on glucose levels are
observed within hours of steroid exposure [35], and appear
to be dose-dependent. A population-based study of over
11,000 patients found that the risk for hyperglycemia in-
creased substantially with increasing daily steroid dose;
odds ratios (ORs) for hyperglycemia were 1.77, 3.02, 5.82
and 10.34 for 1–39 mg/day, 40–79 mg/day, 80–119 mg/
day and ≥120 mg/day of hydrocortisone-equivalent,
respectively [36]. GCs also appear to have a greater impact
on postprandial compared to fasting glucose levels [37].
Glycemic targets and management strategies for
patients with GC-induced hyperglycemia/diabetes are
generally the same as in those with pre-established diabetes
or glucose intolerance in the absence of GC therapy
[38,39] (see Hyperglycemia/Diabetes sections in Practical
Recommendations for the Monitoring, Prevention and
Management of Systemic Corticosteroid-Induced AEs). In
general, GC-induced hyperglycemia improves with dose
reductions and usually reverses when steroid therapy is
discontinued, although some patients may develop persistent
diabetes.Cataracts and glaucoma
The risk of both cataracts and glaucoma is increased in
patients using GCs, and this risk appears to be dose-dependent. GC use is typically associated with the
development of posterior subcapsular cataracts (PSCC)
[40], as opposed to nuclear or cortical cataracts. PSCC
tend to be more visually significant and, therefore,
usually require earlier surgical intervention/removal than
other types of cataracts.
There is inter-individual variation in susceptibility to
PSCC and the incidence varies per individual. Time until
onset is at least 1 year with doses ≥10 mg/day of oral
prednisone (or equivalent). Although PSCC are frequently
seen in patients treated systemically, or even occasionally
in those receiving inhaled corticosteroids (ICSs) [41], they
are more commonly caused secondary to local treatment
(e.g., topical eye drops and periocular or intravitreal
administration).
Glaucoma is the more serious ocular complication of GC
therapy. Systemic corticosteroids can painlessly increase
intraocular pressure, leading to visual field loss, optic disc
cupping, and optic nerve atrophy. Once systemic therapy is
discontinued, the elevation in intraocular pressure often
resolves within a few weeks, but the resultant damage to
the optic nerve is often permanent.
While all patients using systemic steroids are at risk for
elevation in intraocular pressure and glaucoma, certain
groups appear to be at higher risk. Ocular hypertension
and glaucomatous visual field defects have been reported
in patients using systemic steroids with a personal or
family history of open angle glaucoma, diabetes, high
myopia or connective tissue disease (particularly rheuma-
toid arthritis) [42]. To reduce the risk of steroid-induced
glaucoma, it is important to screen patients for these risk
factors. All patients who may require long-term systemic
GC therapy with a positive history for glaucomatous risk
factors should be referred to an ophthalmologist for a
comprehensive ocular assessment (see Ophthalmologic
Examination section).
Central serous chorioretinopathy (CSCR) is also associated
with systemic GC use. This type of chorioretinopathy is
associated with the formation of subretinal fluid in the
macular region which leads to separation of the retina
from its underlying photoreceptors. This manifests as
central visual blur and reduced visual acuity. Therefore,
GCs should be used cautiously in patients with a
history of CSCR [43].
Cutaneous adverse events
Corticosteroids induce atrophic changes in the skin
that can lead to skin thinning and fragility, purpura
and red striae. Skin thinning and purpura are usually
reversible upon discontinuation of therapy, but striae
are permanent.
Purpura generally affect the sun exposed areas of the
dorsum of the hands and forearms, as well as the sides
of the neck, face, and lower legs, and are usually not
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generally appear on the thighs, buttocks, shoulders and
abdomen.
Impairment of wound healing is another common, and
potentially serious, side effect of systemic GC use.
Corticosteroids interfere with the natural wound-healing
process by inhibiting leukocyte and macrophage infiltra-
tion, decreasing collagen synthesis and wound maturation,
and reducing keratinocyte growth factor expression after
skin injury [44]. Some topical and systemic agents may
help counter the effects of corticosteroids on wound
healing, including epidermal growth factor, transforming
growth factor beta, platelet-derived growth factor, and
tetrachlorodecaoxygen [45].
Gastrointestinal events
GC therapy has been associated with an increased risk
of several adverse GI events including gastritis, ulcer
formation with perforation and hemorrhage, dyspepsia,
abdominal distension and esophageal ulceration. Despite
the commonly held perception that steroid use increases
the risk of peptic ulcer disease, large meta-analyses of
randomized, controlled trials have failed to show a
significant association between GC use and peptic ulcers
[46,47]. Recent evidence suggests that the risk of peptic
ulcer disease due to corticosteroids alone is low, but
increases significantly when these agents are used in
combination with non-steroidal anti-inflammatory drugs
(NSAIDS) [48]. One meta-analysis found a nearly four-
fold increased risk of GI events among GC users who
were also taking NSAIDS vs. those not using NSAIDS
[49]. Messer et al. also found a four-fold increased risk
of GI events with concomitant NSAID and GC use vs.
non-use of either drug [50].
Acute pancreatitis has also been reported to be an
adverse effect of corticosteroid use. A Swedish population-
based, case–control study demonstrated an increased risk
of acute pancreatitis after exposure to GC therapy [51].
Overall, the OR for developing acute pancreatitis was 1.53
(95% confidence interval [CI], 1.27-1.84) in GC users
vs. non-users, with the risk of developing pancreatitis
appearing to be greatest 4–14 days after subjects
received treatment [51]. However, other evidence
suggests that the underlying disease processes for
which GC therapy is prescribed (particularly systemic
lupus erythematosus [SLE]) may be more likely causes
of pancreatitis than GC use [52].
Cardiovascular disease and dyslipidemia
GC use is associated with AEs that are known to be
associated with a higher CVD risk, including hypertension,
hyperglycemia, and obesity. A population-based study
comparing 68,781 GC users and 82,202 non-users
found the rate of CV events to be significantly higherin patients prescribed high GC doses (≥7.5 mg/day of
prednisone or equivalent) vs. those who had not received
GCs (adjusted relative risk [RR], 2.56; 95% CI, 2.18-2.99);
CV risk was not increased in patients using <7.5 mg of
prednisone daily [53]. Another large, retrospective case–
control study found current GC use to be associated with
a significantly increased risk of heart failure (adjusted OR,
2.66; 95% CI, 2.46-2.87) and ischemic heart disease (OR,
1.20; 95% CI, 1.11-1.29), but not ischemic stroke or transi-
ent ischemic attack (TIA). CV risk was found to be greater
with higher GC doses and with current vs. past use [54].
Population-based studies conducted in Northern
Europe have also noted an increased risk of new-onset
atrial fibrillation (AF) and flutter in GC users [55,56].
In these studies, the risk of AF was significantly greater
with current or recent use (i.e., within 1 month) of
high GC doses or with long-term use of these agents.
Serious CV events, including arrhythmias and sudden
death, have also been reported with pulse GC therapy.
However, these events are rare and have occurred
primarily in patients with underlying kidney or heart
disease [57]. Although it is unclear whether these serious
AEs are due to GC use or the underlying condition, some
experts recommend continuous cardiac monitoring in
patients with significant cardiac or kidney disease receiving
pulse therapy. Longer infusion times (2–3 h) for pulse GC
therapy should be considered in patients who are at high
risk of CVD [58].
Findings from studies examining the relationship
between GC use and dyslipidemia have been conflicting.
While clinical trials involving patients with SLE have
shown prednisone doses >10 mg/day to be associated
with hyperlipidemia [59,60], another trial conducted in
patients with rheumatoid arthritis found no adverse
effect of prednisone (20 mg/day tapered to 5 mg/day
over 3 months) on serum lipids after adjustment for
other risk factors [61]. In fact, findings from a study
examining data from 15,004 participants in the Third
National Health and Nutrition Examination Survey suggest
that GC use may have a beneficial effect on lipids in adults
≥60 years of age [62]. Despite the conflicting evidence,
regular monitoring of lipids (as well as other traditional
risk factors for CVD) is recommended in patients using
GCs at high doses or for prolonged periods (see CV
Risk and Dyslipidemia section).Myopathy
Corticosteroids have direct catabolic effects on skeletal
muscles that can lead to reductions in muscle protein
synthesis and protein catabolism and, ultimately, muscle
weakness. Myopathy generally develops over several
weeks to months of GC use. Patients typically present
with proximal muscle weakness and atrophy in both
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tenderness, however, are not observed. [58,63].
Although there is some variation in the dose and
duration of GC treatment prior to the onset of myopathy, it
is more common in patients treated with ≥ 10 mg/day of
prednisone or equivalent [64]. Also, the higher the GC dose
utilized, the more rapid the onset of muscle weakness.
There is no definitive diagnostic test for GC-induced
myopathy and, therefore, the diagnosis is one of exclusion.
Symptoms generally improve within 3 to 4 weeks of dose
reductions, and usually resolve after discontinuation of GC
therapy [64]. Evidence also suggests that both resistance
and endurance exercise may help attenuate GC-induced
muscle atrophy [65].
Critical illness myopathy may also develop in patients
requiring large doses of IV GCs and neuromuscular
blocking agents. It is characterized by severe, diffuse
proximal and distal weakness that develops over several
days. Although it is usually reversible, critical illness
myopathy can lead to prolonged intensive care unit
(ICU) admissions, increased length of hospital stays,
severe necrotizing myopathy and increased mortality
[58,63,66]. Treatment is directed toward discontinuation
of GC therapy or dose reductions as soon as possible, as
well as aggressive management of underlying medical
comorbidities.
Psychiatric and cognitive disturbances
GC use can lead to a wide range of psychiatric and cognitive
disturbances, including memory impairment, agitation,
anxiety, fear, hypomania, insomnia, irritability, lethargy,
mood lability, and even psychosis. These AEs can
emerge as early as 1 week after initiating corticosteroid
therapy, and appear to be dependent on dose and dur-
ation of therapy [67,68]. A family history of depression
or alcoholism has also been reported as a risk factor
for the development of GC-related affective disorders
[69]. Individuals who develop psychiatric manifestations
on short courses of GCs most commonly report
euphoria, while those on long-term therapy tend to
develop depressive symptoms [68,70,71].
GC therapy may also be associated with sleep disturbances
and unpleasant dreams [72]; the risk of these events
can potentially be decreased by modifying the timing of
GC administration (e.g., a single morning dose) and/or
night-time administration of drugs with sedative effects.
A decline in declarative and working memory has also
been reported with GC therapy; these effects appear to
be dose-dependent and frequently occur during the first
few weeks of therapy [73]. Partial loss of explicit
memory has been reported in patients treated with
prednisone doses of 5 to 40 mg/day for at least 1 year
[74]. Older patients appear to be more susceptible to
memory impairment with less protracted treatment.GC-induced psychosis usually only occurs with the
use of high doses (>20 mg of prednisone or equivalent)
for prolonged periods [75]. In patients with SLE, low
serum albumin levels may also be predictive of GC-
induced psychosis [76]. For patients with persistent
symptoms of psychosis, antipsychotic therapy may be
required [63].
Most patients with psychiatric reactions to corticosteroids
usually recover from these symptoms with dose reduc-
tions or upon cessation of therapy. Lithium has also
been found to be effective for both the prophylaxis and
management of GC-related affective disorders [77].
Immunosuppression
The mechanisms by which corticosteroids inhibit the
immune system and decrease inflammation may predis-
pose patients to infection. A meta-analysis of 71 clinical
trials involving over 2000 patients randomly allocated to
systemic GC therapy found the overall rate of infectious
complications to be significantly higher in patients using
systemic corticosteroids vs. control subjects (RR, 1.6; 95%
CI, 1.3-1.9; P < 0.001). However, the rate was not increased
in patients given a daily dose of < 10 mg or a cumulative
dose of < 700 mg of prednisone [78].
In addition to GC dose, other factors influencing the
risk of infection include: the underlying disorder, patient
age, and concomitant use of immunosuppressive or
biologic therapies [48,79]. A study comparing the infec-
tion risk posed by biologic therapies vs. non-biological
disease-modifying antirheumatic drugs (DMARDs) in
patients with rheumatoid arthritis found baseline GC
use to be the factor most strongly associated with
serious infections [80].
Patients using GCs appear to be particularly susceptible
to invasive fungal and viral infections; this is especially true
in bone marrow transplant recipients [45]. Older patients
and those with lower functional status are also at higher
risk for infections with steroid use. It is important to note
that early recognition of infections in patients taking GCs
is often difficult [48]. GC users may not manifest signs and
symptoms of infection as clearly as non-users, due to the
inhibition of cytokine release and associated reduction in
inflammatory and febrile responses.
Children & adolescents
The GC-induced AEs seen in adults can also occur in the
pediatric population, including osteoporosis, hyperglycemia,
Cushing’s syndrome and AS. However, one side effect that
is unique to children is growth suppression.
Growth suppression
Oral GC therapy has been associated with a delay in
growth and puberty in children with asthma and other
childhood diseases such as nephrotic syndrome [81-85].
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compromised in children with a history of GC use
[81,86]. Lai and colleagues reported growth data on 224
children with mild-to-moderate cystic fibrosis who par-
ticipated in a trial of alternate-day prednisone (1 or
2 mg/kg body weight) vs. placebo [86]. Subjects started
prednisone treatment at a mean age of 9.5 years (range,
6 to 14 years); treatment was discontinued at mean ages
of 12.9 and 13.8 years for the high-dose and low-dose
groups, respectively, and growth was followed for an
additional 6 to 7 years after prednisone discontinuation.
At the time of final follow-up, 152 patients (68%) were
older than 18 years of age. Mean height after age 18 years
was found to be significantly lower in boys previously
treated with either high- or low-dose prednisone vs.
placebo. When indices of pulmonary status were controlled
for, the negative association between the use of prednisone
and height remained strong in boys. No persistent growth
impairment was noted in female subjects.
It is important to note that although growth can be an
independent adverse effect of corticosteroid therapy, it
can also be a sign of AS.Adrenal suppression
AS is the most common cause of adrenal insufficiency
in children. The rate of adrenal crisis or death related
to AS is unknown, however, adrenal insufficiency is
associated with higher mortality in the pediatric popu-
lation, highlighting the importance of recognition [29].
As in adults, the symptoms of AS are non-specific;
therefore, the condition may go unrecognized until
exposure to a physiological stress (illness, surgery or
injury), which may result in adrenal crisis. Children
with adrenal crisis secondary to AS may present with
hypotension, shock, decreased consciousness, lethargy,
unexplained hypoglycemia, seizures or even death (see
Table 4) [87-91].
Several cases of pediatric AS have been reported in the
literature, including adrenal crises in children requiring
hospitalization and prolonged ICU stays [92,93]. To our
knowledge, there have been no published population
studies looking at the frequency of symptomatic AS
associated with systemic GCs. However, interim results
from a national survey examining AS associated with
any form of GC in the Canadian pediatric population
over a two-year period have reported 44 cases of symp-
tomatic AS, 6 of which presented as adrenal crisis [90]. A
recent meta-analysis of AS in children treated with acute
lymphoblastic leukaemia (ALL) found biochemical
evidence of AS immediately following GC discontinuation
in nearly all 189 patients [93]. AS resolved within a few
weeks in most patients, but persisted for up to 34 weeks
in others.Although some studies have suggested that higher
doses and longer durations of GC treatment may be
risk factors for AS, these findings have not been
consistent across trials [30,93-96]. Even relatively low
pharmacologic GC doses are significantly higher than
physiologic doses, making AS a potential risk. For
example, the standard dose of prednisone for the treatment
of nephrotic syndrome in children is 2 mg/kg/day. When
converted into dose/m2, this dose is approximately 20
times the physiologic dose of GCs, highlighting the poten-
tial for AS with similar therapies. Currently, the Pediatric
Endocrine Society recommends that AS be considered in
all children who have received supraphysiological doses of
GCs (>8-12 mg/m2/day hydrocortisone or equivalent) for
greater than 2 weeks [29].
Hyperglycemia and diabetes
Most cases of medication-induced diabetes in children
are associated with GC use. Steroid-induced hypergly-
cemia and diabetes have been reported in post-transplant
patients, children with ALL, and those undergoing treat-
ment for nephrotic syndrome [97,98]. There have also
been reports of diabetic ketoacidosis at presentation in
these children [97,98].
There is currently limited data describing risk factors for
hyperglycemia and diabetes secondary to GC use in the
pediatric population. Although obesity has been described
as a potential risk factor, a retrospective Canadian
study of children < 18 years of age found that,
compared to those with established type 2 diabetes,
those with medication-induced diabetes were less
likely to be obese, have a positive family history of
type 2 diabetes, and have obesity-related comorbidities
(e.g., dyslipidemia, hypertension or elevated alanine
aminotransferase levels) [97]. Therefore, evaluating for
the typical type 2 diabetes risk factors may not be
sufficient for identifying children at-risk of developing
steroid-induced hyperglycemia or diabetes.
Cushing’s syndrome
GC therapy is by far the most common cause of Cushing’s
syndrome in children. The clinical presentation in the
pediatric population is similar to that in adults, and
includes truncal obesity, skin changes and hypertension. In
children, however, growth deceleration is also observed
[99]. Children who develop features of Cushing’s syndrome
as a result of GC therapy are at higher risk of experiencing
AS. Therefore, HPA-axis function should be evaluated
prior to discontinuing steroid therapy in children with
Cushingoid features [88,89].
Osteoporosis
A number of studies have reported decreased bone
density in children taking oral corticosteroids [100-107].
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of general practitioners in the United Kingdom to esti-
mate the fracture incidence rates in children aged 4–
17 years taking oral steroids (n = 37,562) and those
taking non-systemic corticosteroids (n = 345,748) [108].
The risk of fracture was increased in children who
received four or more courses of oral corticosteroids
(adjusted OR, 1.32; 95% CI, 1.03-1.69). Of the various
fracture types, the risk of humerus fracture was doubled
in these children (adjusted OR, 2.17; 95% CI, 1.01-4.67).
Children who stopped taking oral corticosteroids had a
comparable risk of fracture to those in the control
group [108].
Vertebral fractures are an under-recognized manifest-
ation of osteoporosis in children, in part due to the fact
that such fractures are often asymptomatic (even when
moderate or severe) [109-112]. Similar to adults, verte-
bral fractures in GC-treated children are most frequently
noted in the mid-thoracic region and at the thoracolum-
bar junction [109-112]. Recently, it has been shown that
in children with GC-treated rheumatic disorders, 7%
had prevalent vertebral fractures around the time of GC
initiation, and 6% manifested incident vertebral fractures
at 1 year [110,111]. Children with rheumatic conditions
and incident vertebral fractures at 12 months received
twice as much steroid, and had greater increases in BMI
and declines in spine BMD Z-scores [111]. These studies
have played an important role in furthering our under-
standing of the osteoporosis burden manifesting as
vertebral fractures in steroid-treated children.
Practical recommendations for the monitoring,
prevention and management of systemic
corticosteroid-induced adverse events
Assessment and monitoring
Before initiating long-term systemic corticosteroid therapy,
a thorough history and physical examination should be
performed to assess for risk factors or pre-existing condi-
tions that may potentially be exacerbated by GC therapy,
such as diabetes, dyslipidemia, CVD, GI disorders, affective
disorders, or osteoporosis. At a minimum, baseline measures
of body weight, height, BMD and blood pressure should
be obtained, along with laboratory assessments that
include a complete blood count (CBC), blood glucose
values, and lipid profile (Table 5). In children, nutritional
and pubertal status should also be examined.
Symptoms of and/or exposure to serious infections
should also be assessed as corticosteroids are contrain-
dicated in patients with untreated systemic infections.
Patients without a history of chicken pox should be
advised to avoid close contact with people who have
chickenpox or shingles, and to seek urgent medical
advice if they are exposed [1]. Concomitant use of other
medications should also be assessed before initiatingtherapy as significant drug interactions have been noted
between GCs and several drug classes [1,8] (see Table 6).
Females of childbearing age should also be questioned
about the possibility of pregnancy. GC use in pregnancy
may increase the risk of cleft palate in offspring,
although the absolute risk appears to be low [48].
The above-mentioned parameters should be monitored
regularly. Specific recommendations for the assessment
and monitoring of BMD and fracture risk, diabetes, CV
risk and dyslipidemia, AS, growth, and ophthalmologic
events are provided below.
BMD and fracture risk in adults
The authors recommend annual height measurement
and questioning for incident fragility fractures in adults
receiving GC therapy. Assessment of BMD at baseline
and after 1 year of GC therapy in adults who are
expected to be on prednisone ≥5 mg/day (or equivalent)
for over 3 months is also recommended. If BMD is
stable at the 1-year follow-up and fracture risk is low,
then subsequent BMD assessments can be performed
every 2–3 years (Table 5). However, if bone density has
decreased at the initial 1-year follow-up, both BMD and
fracture risk should be assessed annually. Guidelines
currently recommend using the World Health Organiza-
tion’s (WHO) Fracture Risk Assessment Tool (FRAX) to
estimate fracture risk in order to determine which
patients should be started on pharmacologic therapy for
fracture prevention [113-117]. However, it is important
to note that FRAX does not differentiate between past
and present GC use or steroid doses. Experts recom-
mend adjusting FRAX risk according to GC dose [118]
(see Table 7). For high-doses (≥7.5 mg/day of prednisol-
one or equivalent), 10-year hip fracture risk is increased
by ~20% and major osteoporotic fracture risk by ~15%,
depending on age. For medium doses (2.5-7.5 mg daily),
the unadjusted FRAX value can be used, and for low-
dose exposure (<2.5 mg daily of prednisolone or equiva-
lent), the probability of a major fracture is decreased by
approximately 20%, depending on age.
A lateral spine x-ray is also recommended in
adults ≥65 years to assess for vertebral fractures.
BMD and fracture risk in children
In adults, a single BMD assessment can help predict the
likelihood of fracture due to age-related osteoporosis. In
children with GC-induced osteoporosis, however, this
relationship is not as evident. Therefore, experts have
recommended serial BMD assessments in at-risk children
as well as in those displaying evidence of growth
failure [119]. Since BMD results need to be carefully
interpreted in relation to the child’s gender, age, height,
and weight, as well as the underlying disease requiring GC
therapy, referral to a specialist for assessment of bone
Table 5 Assessment and monitoring of patients scheduled for long-term systemic corticosteroid therapy
Baseline: Physical: Investigations:
• Weight • CBC
• Height • Glucose (FPG, A1C, 2-h OGTT or casual PG)
• BMI • Lipids (LDL-C, HDL-C, TC, non-HDL-C, TG, ± apo B)
• Blood pressure • BMD
Subsequent monitoring: Bone health (adults):
• Annual height measurement, and questionnaire for incident fragility fracture
• BMD 1-year post GC initiation
→ If stable: assess every 2–3 years
→ If decreased: assess annually
• Lateral spine x-ray in adults ≥65 years to examine for vertebral fractures
• Use FRAX to estimate fracture risk
→ Available at: http://www.sheffield.ac.uk/FRAX
• Consider referral to endocrinologist/rheumatologist if fracture risk is high and/or BMD is decreasing
Bone health (children):
• Consider a baseline spine BMD and lateral spine x-ray in children receiving ≥3 months of GC therapy
• Repeat at intervals (typically yearly) if there is persistence of risk factors:
→Ongoing steroid therapy →Declines in spine BMD Z-scores or BMC
→ Low trauma extremity fractures → Growth deceleration
→ Back pain → Cushingoid features
• Referral to a pediatric bone health specialist if there is evidence of bone fragility (low-trauma extremity
or vertebral fractures) or declines in BMD Z-scores
HPA-axis functioning (see Table 8)
Growth (Children & Adolescents):
• Monitor every 6 months and plot on growth curve
• If growth velocity inadequate, refer to pediatric endocrinologist for further assessment
Dyslipidemia and CV Risk (adults):
• Assess lipids 1 month after GC initiation, then every 6–12 months
• Assess 10-year CV risk using FRS
→ Available at: https://www.cvdriskchecksecure.com/FraminghamRiskScore.aspx
Hyperglycemia/Diabetes:
• Screen for classic symptoms at every visit: polyuria, polydipsia, weight loss
• Monitor glucose parameters:
→ For at least 48 hours after GC initiation [38]
→ Then every 3–6 months for first year; annually thereafter
• In children, monitor FPG annually
→ Annual OGTT if child is obese or has multiple risk factors for diabetes
Ophthalmologic Examination:
• Refer for annual examination by ophthalmologist
→ Earlier examination for those with symptoms of cataracts
• Early referral for intra-ocular pressure assessment if:
→ Personal or family history of open angle glaucoma →Diabetes mellitus
→Diabetes mellitus → High myopia
→ High myopia → Connective tissue disease (particularly rheumatoid arthritis)
→ Connective tissue disease (particularly rheumatoid arthritis)
BMI body mass index, BMC bone mineral content, BMD bone mineral density, CBC complete blood count, FPG fasting plasma glucose, A1C glycated hemoglobin,
PG plasma glucose, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides, apo B apolipoprotein B, FRAX
Fracture Risk Assessment Tool, CV cardiovascular, FRS Framingham Risk Score, OGTT oral glucose tolerance test.
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Table 6 Major drug interactions with systemic GCs [1,8]
Interacting drug class Effect Recommendation/comment
Anticonvulsants (e.g., carbamazepine,
phenobarbital, phenytoin)
• ↓ GC exposure and efficacy; may persist for weeks
following discontinuation of anticonvulsant
• Closely monitor outcomes of concomitant use
• GC dose alterations may be required
Anticoagulants (e.g., warfarin) • May ↑ anticoagulant effects of warfarin and ↑ risk of
GI bleeding
• Monitor INR closely
• Significant alteration in warfarin dose will likely be
required within 3–7 days of GC initiation
Antifungals (e.g., itraconazole,
ketoconazole)
• ↑ GC exposure and toxicity • Monitor concurrent use for signs of GC overdose
(fluid retention, hypertension, hyperglycemia)
• Dose alteration of methylprednisolone and
dexamethasone may be needed (prednisone and
prednisolone not affected to a clinically relevant
degree by this interaction)
Antidiabetic agents • GC initiation can lead to glucose dysregulation,
thereby counteracting the effects of antidiabetic
drugs
• ↑ frequency of BG monitoring when initiating GC
therapy
• Adjust antidiabetic therapy based on BG results
Antibiotics (macrolides)
(e.g., clarithromycin)
• ↑ GC exposure and toxicity • Monitor concurrent use for signs of GC overdose
(fluid retention, hypertension, hyperglycemia)
• Dose alteration of methylprednisolone and
dexamethasone may be needed (prednisone and
prednisolone not affected to a clinically relevant
degree by this interaction)
Antivirals (e.g., atazanavir, indinavir,
ritonavir, saquinavir)
• ↑ GC exposure and toxicity • Monitor concurrent use for signs of GC overdose
(fluid retention, hypertension, hyperglycemia)
• Dexamethasone may ↑ levels of indinavir and
saquinavir
• Dose alteration of methylprednisolone and
dexamethasone may be needed (prednisone and
prednisolone not affected to a clinically relevant
degree by this interaction)
• Monitor antiviral efficacy of indinavir and
saquinavir if patient is taking dexamethasone
Anti-infectives (e.g., efavirenz,
nevirapine, rifampin)
• ↓ GC exposure and efficacy; may persist for weeks
following discontinuation of anti-infective
• Closely monitor outcomes, especially in transplant
recipients
• ↑ GC dose accordingly
Diuretics, potassium wasting
(e.g., furosemide, HCTZ)
• GCs may ↑ kaliuretic effects of these diuretics • Monitor potassium levels to determine whether
alteration of diuretic therapy and/or potassium
supplementation is needed
Live vaccines • Immunization with live vaccines while taking
immunosuppressive GC doses (40 mg/day of
prednisolone [or equivalent] for > 7 days) may
increase risk of both generalized and life-threatening
infections
• Postpone live vaccines for at least 3 months after
high-dose GC therapy is discontinued
NSAIDS • May ↑ risk of GI ulcers when given concomitantly
with corticosteroids
• Consider use of PPI if person is at risk of GI ulcers
GC glucocorticoid, INR international normalized ratio, BG blood glucose, GI gastrointestinal, HCTZ hydrochlorothiazide, PPI proton pump inhibitor, NSAIDS non-steroidal
anti-inflammatory drugs.
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the same time, the bone health assessment of a child on
chronic GC therapy needs to be extended beyond BMD in
order to identify risk factors as well as early manifestations
of osteoporosis. As such, bone health monitoring in
pediatric chronic GC users includes an evaluation of
calcium and vitamin D intake, back pain, physical activity,
and disease-related risk factors for attenuated bone mineral
accrual and bone loss (such as chronic inflammation and
disuse). A spine radiograph should be considered in at-risk
children with a prior history of vertebral fractures, back
pain, chronic GC exposure (> 3 months), poorly-controlled
inflammatory disease, significantly impaired mobility, orreductions in spine BMD Z-scores on serial measurements
(Table 5).Osteonecrosis (adults and children)
Because early diagnosis and appropriate intervention can
prevent or delay the progression of osteonecrosis and
the need for joint replacement, patients using high-dose
GC therapy or those treated with GCs for prolonged
periods should be evaluated for joint pain and decreased
range of motion at each visit [58]. Magnetic resonance
imaging should be considered in adult or pediatric
patients presenting with these signs or symptoms [16].
Table 7 Percentage adjustment of 10-year probabilities
of a hip fracture or a major osteoporotic fracture by age




40 50 60 70 80 90 All
ages
Hip fracture
Low < 2.5 −40 −40 −40 −40 −30 −30 −35
Medium* 2.5–7.5
High≥ 7.5 +25 +25 +25 +20 +10 +10 +20
Major osteoporotic
fracture
Low < 2.5 −20 −20 −15 −20 −20 −20 −20
Medium* 2.5–7.5
High≥ 7.5 +20 +20 +15 +15 +10 +10 +15
Reproduced from Kanis et al. 2011 [118].
*No adjustment.
Table 8 Screening recommendations for AS [91]
When to Screen?
• Patient has received systemic corticosteroids for:
> 2 consecutive weeks or >3 cumulative weeks in the last 6 months
• Patient has persistent symptoms of AS:
– Weakness/fatigue, malaise, nausea, vomiting, diarrhea, abdominal
pain, headache (usually in the morning), poor weight gain and/or
growth in children, myalgia, arthralgia, psychiatric symptoms,
hypotension*, hypoglycemia*
How to Screen?
• Measure early morning cortisol‡
– GC dose tapered to physiologic dose prior to test
– No oral GCs the evening and morning prior to the test†
– Must be completed by 8:00 am or earlier
– Fasting not required
• If morning cortisol is normal but patient has symptoms of AS, perform
low-dose ACTH stimulation test‡ to confirm diagnosis:
– 1 μg of cosyntropin; cortisol levels taken at 0, 15–20 and
30 minutes**
– Peak cortisol < 500 nmol/L = AS (peak >500 nmol/L is normal)
When to be Concerned?
• Early morning cortisol < 85 nmol/L = diagnosis of AS
• Early morning cortisol < laboratory normal = possible AS; consider
endocrinology referral for confirmation of diagnosis
Modified from Ahmet et al., 2011 [91].
AS adrenal suppression, ACTH adrenocorticotropic hormone, GCs
glucocorticoids.
*Symptoms of adrenal crisis require emergent management.
†Patients must be switched to hydrocortisone for this to apply. If the patient is
on a GC with a longer half-life (e.g., dexamethasone), then morning cortisol
will remain suppressed due to the medication 24 hours after a dose.
**Ideally, GCs should be withdrawn prior to this test to avoid ongoing HPA
suppression or falsely elevated cortisol levels in the case of GCs that are
detected by the cortisol assay. In patients believed to be at high risk of adrenal
crisis without GC treatment, dexamethasone can be used. Dexamethasone
would be associated with suppression of the baseline cortisol level, but ACTH-
stimulated cortisol levels should reflect endogenous production since
dexamethasone typically does not cross-react with cortisol assays.
‡Exogenous estrogen therapy increases serum cortisol; therefore, cortisol levels
will not be reliable in the setting of estrogen use.
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Health care providers must be aware of the risk of AS in
patients who have received supraphysiological GC doses.
The risk of AS is low in patients who have been treated
with GC therapy for less than 1 week [120]. However, as
is seen following longer courses of GC treatment, AS
may result from multiple short courses of high-dose
therapy. Based on current evidence, experts recommend
that physicians be aware of the risk of AS in patients
receiving supraphysiological GC doses for >2 weeks,
those who have received multiple courses of oral
steroids totaling >3 weeks in the last 6 months, or in
patients presenting with symptoms of AS (including
growth failure in children) (see Table 8) [91].
If AS is suspected, biochemical testing of the HPA axis
should be considered after GC treatment has been reduced
to a physiologic dose. Given the ease and practicality of a
first morning cortisol measurement, it should be consi-
dered for the initial screening of patients at risk for AS.
The test should be performed at 8:00 am or earlier given
that cortisol levels decline throughout the day with natural
circadian rhythm, and both evening and morning GC
doses should be held prior to testing (see Table 8) [91]. If
the 8:00 am cortisol value is below the normal laboratory
reference range, AS is likely present and further GC
withdrawal should occur only once testing has normalized.
It is important to note that the specificity of the first
morning cortisol test approaches 100% if a very low cut-off
value (<85-112 nmol/L) is used. However, the sensitivity of
this test is poor (~60%) [121]. Therefore, a normal cortisol
value does not rule out the presence of AS. If a patient has
signs or symptoms of AS and requires further testing, then
referral to an endocrinologist should be considered.
Clinicians must be aware that exogenous estrogen therapy,
which affects cortisol-binding globulin levels, increasesserum cortisol; therefore, the same thresholds for
diagnosing AS do not apply in the setting of estrogen use.
The insulin tolerance test (ITT) is the definitive test
for evaluation of the HPA axis, but performing this test
is complicated and risky for patients since insulin is
administered to achieve hypoglycemia. The ITT is
contraindicated in children secondary to the risks of
hypoglycemia on the pediatric brain. Therefore, in the
setting of a normal morning cortisol result and the pres-
ence of AS symptoms, the low-dose adrenocorticotropic
hormone (ACTH) stimulation test should be performed
to confirm the diagnosis since it is a sensitive and specific
test for AS [122-124]. The low-dose ACTH stimulation
test involves IV administration of 1 μg of cosyntropin with
measurements of baseline and stimulated serum cortisol
levels to assess the function of the HPA axis. Cortisol
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cosyntropin injection, hence, cortisol measurements are
recommended at 15–20 min and 30 min [124]. Many
protocols also recommend measuring cortisol at 60 min.
A peak cortisol of <500 nmol/L is diagnostic of AS, with
both a sensitivity and specificity of approximately 90%
[122-124] (note that a lower peak cortisol cut-off value
may be required in neonates).
Growth in children
For children receiving GC therapy, growth should be
monitored every 6 months (ideally by using stadiometry
measurements) and measurements should be plotted on an
appropriate growth curve (Table 5). If, after 6 months,
growth velocity appears to be inadequate, the physician
should consider all possible etiologies, including AS, as well
as referral to an endocrinologist [91]. It is also important to
rule out malnutrition as a cause of poor growth [9,119].
CV risk and dyslipidemia
There are currently no evidence-based guidelines for the
monitoring of dyslipidemia and CV risk in patients using
corticosteroid therapy. The authors recommend assessment
of lipid profile at baseline, 1-month after initiating
systemic GC therapy and then every 6–12 months
thereafter (Table 5). Ten-year CV risk should also be
assessed using the Framingham Risk Score (FRS) (https://
www.cvdriskchecksecure.com/FraminghamRiskScore.aspx),
and lipid targets and treatment should be based on the
FRS (see Table 9 for Canadian Cardiovascular Society
recommendations) [125].
Hyperglycemia/diabetes
All patients should be educated about the classic signs
and symptoms of hyperglycemia (polyuria, polydipsia,
unexplained weight loss) so that they are screened for
steroid-induced diabetes if symptoms arise. In adults,
monitoring of glycated hemoglobin (A1C), fasting
plasma glucose (FPG), 2-hour plasma glucose (2-h PG)
(using a 75-g oral glucose tolerance test [OGTT]), or
casual PG (any time of the day without regard to the
interval since the last meal) are recommended (Table 5),
although FPG, casual PG, and A1C may be less sensitive
for diagnosing diabetes. If blood glucose or A1C is
abnormal at baseline, then home blood glucose monitoring
is also recommended.
Glucose investigations should be repeated after
starting GC therapy. In patients taking prednisolone,
some experts have recommended that blood glucose be
monitored within 8 hours of the first dose (i.e., in the
afternoon if once-daily prednisolone is administered in the
morning) [37]. The 2013 Canadian Diabetes Association
(CDA) guidelines recommend that glycemic parameters be
monitored for at least 48 hours after initiation of GCtherapy, regardless of whether or not the patient has dia-
betes [38]. Guidelines for blood glucose monitoring
post-transplant suggest weekly monitoring for four
weeks after transplant, followed by blood glucose
checks at 3 and 6 months post-transplant, then annually
thereafter [126]. A diagnosis of diabetes is confirmed if
A1C is ≥6.5% (in adults), FPG is ≥7.0 mmol/L, 2-hour PG
is ≥11.1 mmol/L or if casual PG is ≥11.1 mmol/L and the
patient has classic symptoms of diabetes [38].
In the absence of screening guidelines for GC-
induced diabetes in children, the authors recommend
that physicians be aware of the risk of hyperglycemia
in children receiving long-term supraphysiological GC
doses and, at a minimum, screen for classic symptoms
[98]. An annual FPG should also be considered.
In children presenting with symptoms suggestive of
diabetes, FPG should be performed. If FPG is not
diagnostic of diabetes in those with symptoms, OGTT is
recommended. The diagnostic criteria for diabetes in
children are the same as for adults [38]. More frequent
screening of glucose parameters should be considered in
children who are at potentially higher risk of developing
hyperglycemia or diabetes, such as transplant recipients,
obese patients, or those with conditions such as ALL or
nephrotic syndrome. Annual OGTT is recommended in
children who are very obese and/or who have multiple
risk factors for type 2 diabetes since this test may be
associated with higher detection rates.
Ophthalmologic examination
Patients on low-to-moderate doses of systemic cortico-
steroids for more than 6–12 months should undergo
annual examination by an ophthalmologist (Table 5). An
earlier examination is required in patients with symp-
toms of cataracts (namely blurred vision), however, this
is generally not considered an ocular emergency that
requires urgent treatment.
Early referral for monitoring of intra-ocular pressure
(glaucoma) is recommended in patients at higher risk of
developing steroid-induced glaucoma, such as those with
a personal or family history of open angle glaucoma,
diabetes mellitus, high myopia, or connective tissue
disease (especially rheumatoid arthritis).
Strategies for the prevention and management of
GC-induced adverse events
General strategies
To minimize the occurrence of steroid-induced AEs, the
lowest effective GC dose should be prescribed for the
minimum period of time required to achieve treatment
goals (Table 10). If possible, consideration should be
given to once-daily, morning administration and/or
intermittent or alternate-day dosing. Any pre-existing
comorbid conditions that may increase the risk of GC-
Table 9 Canadian Cardiovascular Society guidelines for CVD prevention and dyslipidemia management: treatment
thresholds and targets based on Framingham Risk Score (FRS) [125]
Risk level Initiate therapy if: Primary target LDL-C Alternate target
High • Consider treatment in all • ≤2 mmol/L, or • Apo B ≤0.8 g/L
FRS ≥20% • ≥50% ↓ in LDL-C • Non HDL-C ≤2.6 mmol/L
Intermediate • LDL-C ≥3.5 mmol/L • ≤2 mmol/L,or • Apo B ≤0.8 g/L
FRS = 10%-19% • For LDL-C <3.5 consider if: • ≥50% ↓ in LDL-C • Non HDL-C ≤2.6 mmol/L
→ Apo B ≥1.2 g/L, or
→ Non-HDL-C ≥4.3 mmol/L
Low • LDL-C ≥5.0 mmol/L • ≥50% ↓ in LDL-C
FRS <10% • Familial hypercholesterolemia
Adapted from Anderson et al., 2013 [125].
FRS Framingham Risk Score, HDL-C high-density lipoprotein cholesterol, LDL-C, low-density lipoprotein cholesterol, apo B apolipoprotein B.
Table 10 General strategies for the prevention of
GC-induced AEs
• Treat pre-existing comorbid conditions that may increase risk of
GC-associated AEs
• Prescribe lowest effective GC dose for minimum period of time
required to achieve treatment goals
• Administer as single daily dose (given in the morning), if possible
• Consider intermittent or alternate-day dosing, if possible
• Use GC-sparing agents whenever possible (e.g., omalizumab in severe
asthma, azathioprine/cyclophosphamide in vasculitis, methotrexate in
rheumatoid arthritis)
• Advise patients to:
▪ Carry a steroid treatment card
▪ Seek medical attention if they experience mood or behavioural
changes
▪ Avoid contact with persons that have infections, such as shingles,
chickenpox, or measles (unless they are immune)
▪ Not discontinue GC therapy abruptly unless advised to do so by
their physician
▪ Adopt lifestyle recommendations to minimize the risk of weight
gain or other AEs:
▫ Eat a healthy balanced diet, including adequate calcium intake
▫ Smoking cessation
▫ Reduction in alcohol consumption
▫ Regular physical activity
• Regularly monitor for signs/symptoms of AEs
GC glucocorticoid, AEs adverse events.
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initiation, and patients should be instructed to avoid
contact with persons that have infections, such as
shingles, chickenpox or measles. Patients should also be
advised to carry a steroid treatment card and wear a
medical identification tag, and to adopt lifestyle habits
that may help minimize the risk of excessive weight gain
with GC use, such as participation in regular physical
activity and following a healthy, low-calorie diet.
Finally, whenever possible, GC-sparing agents should be
considered. In patients with severe asthma, for example, use
of the anti-immunoglobulin E (IgE) monoclonal antibody,
omalizumab, has been shown to reduce the occurrence of
asthma exacerbations requiring systemic corticosteroid
therapy and to improve symptoms and asthma-related
quality of life [127]. At present, omalizumab is reserved for
patients with difficult to control asthma who have docu-
mented allergies and whose asthma symptoms remain
uncontrolled despite ICS therapy [128].
Specific recommendations
Osteoporosis (adults)
A number of published guidelines have addressed the
prevention and treatment of GC-induced osteoporosis in
adults [113-117,129-131]. According to the American
College of Rheumatology (ACR), adults at low- to medium-
risk of fracture (10-year risk of major osteoporotic fracture
<20%) exposed to ≥7.5 mg/day of prednisone or equivalent
for ≥3 months should be treated with pharmacologic
therapy (see Table 11). All patients at high-risk of fracture
(10-year risk of major osteoporotic fracture >20%) should
receive pharmacologic treatment, irrespective of whether or
not they are on GC therapy [115].
Most guidelines and evidence support the use of
bisphosphonates and teriparatide as first-line therapy for
GC-induced osteoporosis in adults. A number of studies
have demonstrated that the bisphosphonates alendronate,
risedronate and zoledronic acid are effective for the
prevention and treatment of GC-induced bone loss[132-138], although their long-term efficacy on fractures
is not well established [132]. Teriparatide has been shown
to be effective in improving BMD and reducing vertebral
fractures in patients with GC-induced osteoporosis
[139-141]. The ACR recommendations for the use of
teriparatide and bisphosphonates are shown in Table 11
[115].
Although other therapies such as calcitonin, raloxifene
and denosumab may also play a role in the management
of GC-induced osteoporosis in adults, they are not
currently recommended as first-line therapy. Calcitonin
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setting of GC use, but the same protection has not been
observed at the femoral neck or with respect to fracture
risk [142]. The European Medicines Agency (EMA)
recently completed a review of the benefits and risks of
calcitonin-containing medicines and concluded that
there is evidence of a small, increased risk of cancer
(0.7-2.4%) with long-term use of these agents [143].
Therefore, given this risk as well as its lack of efficacy in
reducing fracture risk, calcitonin is not recommended as
first-line therapy for GC-induced osteoporosis. However,
it may be considered when bisphosphonates are contra-
indicated or in those patients who are intolerant to oral
or IV bisphosphonates. Due to its analgesic effect,
calcitonin can also be considered in patients who have
sustained an acute fracture.
A study of postmenopausal women on ≤10 mg/day of
prednisone (or equivalent) for ≥6 months demonstrated
that treatment with raloxifene for 1 year improved spine
and total hip (but not femoral neck) BMD [144].
However, the generalizability of these findings areTable 11 ACR pharmacological recommendations for the prev
adults* [115]
Postmenopausal women and men age ≥50 years starting GC therapy o
duration
Low-risk (10-year fracture risk < 10%) • GC dose < 7
→ no p
• GC dose≥ 7
→ alen
Medium-risk (10-year fracture risk = 10-20%) • GC dose < 7
→ alen
• GC dose≥ 7
→ alen
High-risk (10-year fracture risk > 20%) • Any dose o
▪ If GC dos
→ alen
▪ If GC dos
for > 1 month
→ alen
Premenopausal women and men < 50 years with a history of fragility fr
GC duration: 1–3 months
Non-childbearing potential: • If prednison
• If prednison
Childbearing potential: • No consens
GC duration: >3 months
Non-childbearing potential: • Any dose: a
Childbearing potential: • If prednison
• If prednison
*See text for guidelines related to children.
†In clinical practice, teriparatide is generally reserved for bisphosphonate treatment
adherence to 12 months of bisphosphonate treatment).limited since the study cohort was predominantly Asian
and did not include patients on high-dose GC therapy.
Furthermore, as a selective estrogen receptor modulator,
raloxifene use for osteoporosis prevention and treatment
is limited to the postmenopausal female population.
In animal models, denosumab has been shown to
prevent steroid-induced bone loss and improve bone
strength [145]. A phase 2 trial also found that denosumab
improved lumbar spine BMD in patients with rheumatoid
arthritis treated with corticosteroids and bisphosphonates
[146]. The phase 3 FREEDOM trial found denosumab to
be associated with a slightly increased risk of cellulitis
[147], although the 2-year extension trial found no
increased risk with longer term treatment [148].
In addition to pharmacologic therapy, current guidelines
for GC-induced osteoporosis in adults recommend pre-
ventive measures such as smoking cessation, reduced
alcohol consumption, participation in weight-bearing and
strength-building exercises, falls risk assessment, and cal-
cium and vitamin D supplementation [113-117,129-131].
Cochrane investigators reviewed the available data onention and management of GC-induced osteoporosis in
f ≥3 months’ duration, or prevalent GC therapy of ≥3 months’
.5 mg/day of prednisone or equivalent:
harmacologic treatment
.5 mg/day of prednisone or equivalent:
dronate, risedronate or zoledronic acid
.5 mg/day of prednisone or equivalent:
dronate or risedronate
.5 mg/day of prednisone or equivalent:
dronate, risedronate or zoledronic acid
r duration of GCs justifies initiating prescription therapy
e < 5 mg/day of prednisone or equivalent for≤ 1 month:
dronate, risedronate, or zoledronic acid
e≥ 5 mg/day of prednisone or equivalent for ≤ 1 month or any GC dose
:
dronate, risedronate, zoledronic acid or teriparatide†
acture
e (or equivalent)≥ 5 mg/day: alendronate or risedronate
e (or equivalent)≥ 7.5 mg/day: zoledronic acid
us
lendronate, risedronate, zoledronic acid, teriparatide
e (or equivalent) < 7.5 mg/day: no consensus
e (or equivalent)≥ 7.5 mg/day: alendronate, risedronate, teriparatide†
failures (i.e., new vertebral fracture or ≥2 non-vertebral fractures after
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found that supplementation prevented bone loss at the
lumbar spine and forearm, but had no effect on femoral
neck BMD or fracture incidence [149]. Adults on high-
dose GC therapy should be taking 1200 mg/day of
elemental calcium in divided doses and 800–2000 IU of
vitamin D daily [113,117].
Osteoporosis (children)
There are currently no evidence-based guidelines for the
prevention and treatment of GC-induced osteoporosis in
children. General measures are similar to those de-
scribed above and include: using the lowest effective GC
dose possible for the shortest period of time; proper nu-
trition and maintenance of a healthy weight; promotion
of weight-bearing exercise; vitamin D supplementation
to achieve at least 50 nmol/L, and ideally 75 nmol/L
[150,151]; calcium supplementation (if diet is inadequate
to achieve the current, recommended dietary allowance)
[150]; and the use of GC-sparing agents when possible.
Most of the studies examining bisphosphonate use in
GC-treated children have been observational in nature and
have utilized the intravenous (IV) preparation, pamidronate
[152]. Some evidence suggests that bisphosphonate therapy
increases BMD, promotes reshaping and relieves back
pain from previously fractured vertebral bodies, and is
safe and well-tolerated in children with secondary
osteoporosis [152-155], although long-term safety and
efficacy data is still required. Currently, experts recom-
mend consideration of bisphosphonate therapy in
children with evident bone fragility associated with re-
ductions in BMD parameters, particularly if there is a
persistence of risk factors and, thereby, less likelihood
of spontaneous BMD restitution and growth-mediated
reshaping of vertebral bodies [153].
Osteonecrosis
Initial treatment for osteonecrosis includes bed rest and
non-steroidal or other analgesics to relieve pain. For
patients with early stage or less advanced osteonecrosis,
joint-preserving strategies, such as reducing weight-
bearing activities and core decompression (with or
without marrow transplantation), have been utilized with
varying levels of success. For more advanced disease,
femoral head or total hip replacement surgery is usually
required [16]. Since these replacements generally have a
10-year lifespan, strategies that delay the need for
surgery are desired. Some evidence suggests that
treatment with alendronate may reduce the risk of bone
collapse and delay the need for surgery [156,157].
However, a recent randomized, controlled trial found no
benefit of alendronate vs. placebo in patients with osteo-
necrosis [158]. In children with osteonecrosis in the
leukemia setting, IV pamidronate has been associatedwith significant improvements in pain and mobility
[159,160].
Hyperglycemia and diabetes
Glycemic targets for patients with GC-induced diabetes
should be individualized, but for most patients, FPG and
2-h PG targets of 4.0-7.0 mmol/L and 5–10 mmol/L,
respectively, are recommended (see Table 12) [38].
When possible, referral to a multidisciplinary diabetes
team should be considered. Initial management involves
appropriate lifestyle modification strategies; if targets are
not met with these modifications, pharmacotherapy is
recommended, and the same spectrum of glucose-
lowering medications is used for GC-induced diabetes as
is used for pre-existing type 2 diabetes. If blood glucose
levels are <15 mmol/L, then glucose control can likely
be achieved with non-insulin therapies such as
metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors,
sulfonylureas, meglitinides, or glucagon-like peptide-1
(GLP-1) agonists (Table 12). If a sulfonylurea is selected,
it is important to consider both the dosing frequency of
the GC as well as the duration of action of the insulin
secretagogue. Sulfonylureas with shorter half-lives (i.e.,
glyburide, gliclazide or repaglinide) are more suitable for
patients using once-daily prednisone as they can be
dosed once-per-day along with the GC. Agents with
longer half-lives (e.g., gliclazide MR or glimepiride) may
be more suitable for those using dexamethasone or
shorter-acting GCs that are administered more than
once daily.
If blood glucose levels are >15 mmol/L, then insulin
is usually required to achieve glycemic control. In the
absence of a contraindication, metformin is often
recommended in combination with insulin (Table 12).
A reasonable starting dose for insulin is 0.15-0.3 units/
kg/day. With once-daily morning administration of
prednisone, fasting glucose may be unaffected, but
blood glucose will be higher later in the day. If this
occurs, then an intermediate-acting insulin (such as N
or NPH) or a premixed combination of intermediate-
and fast-acting insulin can be initiated in the morning.
If blood glucose is elevated in the morning as well, then
an evening insulin dose may also be required. If
shorter-acting GCs are administered more than once
per day, or if dexamethasone is used, then both fasting
and non-fasting glucose levels are likely to be affected.
In this case, twice-daily intermediate-acting insulin or
long-acting insulin, such as detemir or glargine, are
recommended; fast-acting insulin may also be required
at mealtimes. In order to prevent hypoglycemia, it is
important to remember to adjust diabetes medications
if GC doses are reduced.
The treatment of GC-induced diabetes in children is
best accomplished through the combined efforts of a
Table 12 Glycemic targets and treatment recommendations for GC-induced diabetes in adults
Glycemic targets for most patients [38]:
A1C: ≤7.0 % FPG: 4.0–7.0 mmol/L 2-hr PPG: 5.0–10.0 mmol/L
Management:
Lifestyle interventions:
• Initiate nutrition therapy and physical activity; if BG targets not met, initiate pharmacotherapy
Pharmacotherapy:
If BG < 15 mmol/L: Non-insulin therapies → • Metformin
• Insulin
secretagogues
→ If using once-daily prednisone, use shorter-acting agents
(e.g., glyburide, gliclazide, repaglinide) dosed once-daily with
prednisone
→ If using dexamethasone or shorter-acting agents > once/day,
use longer-acting agents (e.g., gliclazide MR, glimepiride)
• DPP-4 inhibitor
• GLP-1 agonist
If BG < 15 mmol/L vs. >15 mmol/L Insulin → Starting dose: 0.15-0.3 units/kg/day
→ If using once-daily prednisone in the morning, FPG less affected but BG will be
higher later in the day:
• Initiate intermediate-acting insulin (N or NPH) or a premixed combination of
intermediate- and fast-acting insulin, administered in the morning
• Add evening insulin if FPG is elevated
→ If using dexamethasone or shorter-acting agents > once/day, BG likely to be
affected throughout the entire day:
• Use intermediate-acting insulin twice daily or long-acting insulin
(detemir, glargine)
• Fast-acting insulin at mealtimes can be used in combination with intermediate-
and long-acting insulin
Metformin → Often recommended in combination with insulin
Caution: If reducing the GC dose, adjust diabetes medications to avoid hypoglycemia
A1C glycated hemoglobin, FPG fasting plasma glucose, PPG postprandial plasma glucose, BG blood glucose; DPP-4 dipeptidyl peptidase-4,
GLP-1 glucagon-like peptide-1.
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As with adults, lifestyle interventions should be initiated;
if glycemic targets are not met with these modifications,
insulin must be considered. Many of the other glucose-
lowering agents used in adult patients with type 2
diabetes have not been licensed for use in the pediatric
population and may be contraindicated in children with
complex medical issues [98]. Until the safety and efficacy
of these medications in children are established, they
cannot be recommended for routine clinical use in this
population.Adrenal suppression (AS)
To minimize the risk of developing AS, it is important
to consider the relative suppressive effects of the various
GCs (based on potency and duration of action) prior to
initiating therapy (see Table 3). The lowest effective dose
should be utilized for treatment of the underlying condi-
tion and the dose should be re-evaluated regularly to
determine if further reductions can be instituted. Ifpossible, the GC should be administered once-daily in
the morning.
Currently, evidence-based recommendations are lack-
ing for withdrawal of high-dose GC treatment and
management of individuals with biochemical evidence of
AS. If high-dose GC therapy is no longer required, then
GC doses can be reduced relatively quickly from pharma-
cologic to physiologic doses. Examples of withdrawal
regimens for both adults and children are provided in
Tables 13 and 14, respectively. These tables present
modest, but safe, approaches to GC withdrawal and
assume that the clinician has access to testing. However, in
the absence of evidence-based guidelines, some physicians
may choose to withdraw GC therapy gradually without
testing. Regardless of the withdrawal regimen chosen,
clinicians need to be aware of the symptoms of AS and to
slow the withdrawal regimen should these symptoms arise.
Screening tests should be considered to assess adrenal
function as GC therapy is being withdrawn. Screening
should occur before tapering to less than a physiologic
dose (Tables 13 and 14) [161,162]. When possible,
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been tapered to a once-daily physiological dose (prefera-
bly hydrocortisone, which has a shorter half-life).
Symptomatic AS should be treated with daily physio-
logic replacement doses of GC plus “stress doses” during
physiological stress (intercurrent illness, injury or
surgery) (see Tables 15 and 16). This treatment model
replicates the physiological response of the healthy adrenal
gland in order to prevent an adrenal crisis. Theoretically,
an individual with biochemical evidence of AS in the
absence of symptoms is also at risk of adrenal crisis and
should receive “stress doses” of GC during physiological
stress, with or without daily physiologic GC. To our
knowledge, there is no evidence to support or refute
this practice. The safest approach would be to treat
asymptomatic patients with biochemical evidence of
AS no differently than those with symptomatic AS. At a
minimum, these patients should be aware of their
diagnosis and be provided with an information card
that outlines the need to receive GC “stress doses”
during critical illness or surgery (see Tables 15 and 16).Table 13 Prednisone tapering regimen for adults
1. Reduce dose by 2.5- to 5.0-mg decrements every 3–7 days until physiolog
of GC therapy may be recommended if risk of disease relapse is a concern
2. Switch to hydrocortisone 20 mg once-daily, given in the morning
3. Gradually reduce hydrocortisone dose by 2.5 mg over weeks to months
4. Discontinue/continue hydrocortisone based on assessment of morning co
< 85 nmol/L: HPA-axis has not recovered
→ continue hydrocortisone
→ re-evaluate patient in 4–6 weeks
85-275 nmol/L: Suspicious for AS
→ Continue hydrocortisone
→ Further testing of HPA axis or re-e
→ If further evaluation of HPA axis is
▪ ITT (gold-standard but not widely
▪ ACTH stimulation testing (see bel
276-500 nmol/L: HPA-axis function is likely adequate fo
preventing adrenal crisis at times of s
→ Discontinue hydrocortisone
→ Monitor for signs & symptoms of A
→ Consider further evaluation of HPA
consider empiric therapy with high-d
> 500 nmol/L: HPA axis is intact
→ discontinue hydrocortisone
↓
If ACTH stimulation testi
Peak cortisol rises to > 500 nmol/L: HPA axis intact and GC can be discon
Peak cortisol < 500 nmol/L: Steroids required at times of stress an
AS adrenal suppression, GC glucocorticoid, HPA hypothalamic-pituitary-adrenal, ACT
Note: Exogenous estrogen therapy increases serum cortisol; therefore, the same thConsideration should be made to educate patients
about the risk of AS if they have been treated with GC
therapy within the last year, but have not had testing to
rule out AS. In the event of severe illness or surgery,
stress dose steroids should be considered to prevent
adrenal crisis.
Growth
The potency of dexamethasone and betamethasone in
suppressing growth has been shown to be nearly 18 times
higher than that of prednisolone [163]. Therefore, to reduce
the risk of growth suppression in children, lower potency
agents, such as prednisolone, should be used whenever
possible. Consideration should also be given to alternate-
day dosing (if possible) since evidence suggests that the use
of lower doses of prednisolone (10–15 mg/day or < 0.5 mg/
kg/day single dose) on alternate days does not significantly
slow growth velocity [9].
There is currently insufficient evidence to support the use
of recombinant human growth hormone (rhGH) for the
treatment/prevention of GC-induced growth suppression.ic dose (5 to 7.5 mg of prednisone per day) is reached; slower tapering
rtisol:




r daily activities in a non-stressed state, but may be inadequate for
tress or illness
S
axis to determine if function is also adequate for stressed states or
ose steroids during times of stress
ng is performed and:
tinued
d illness until normal ACTH response is noted
H adrenocorticotropic hormone, ITT insulin tolerance test.
resholds for diagnosing AS do not apply in the setting of estrogen use.
Table 14 Prednisone tapering regimen for children
1. Taper GC dose as guided by underlying condition until 30 mg/m2/day of hydrocortisone equivalent is reached (if taper not required for underlying
condition, reduce to 30 mg/m2/day)
2. Then taper by 10-20% every 3–7 days until patient is on physiological GC dose (8–10 mg/m2/day hydrocortisone equivalent)
3. Switch to hydrocortisone 8–10 mg/m2/day, given in the morning
4. Discontinue/continue hydrocortisone based on assessment of morning cortisol:
< 171 nmol/L*: HPA axis has not recovered
→ continue daily hydrocortisone
→ continue stress hydrocortisone as needed
→ re-evaluate patient in 4–6 weeks
> 500 nmol/L: HPA axis is intact
→ discontinue daily and stress hydrocortisone
171*-500 nmol/L: Sufficient GC production for day-to-day functioning†
Further evaluation required to determine if stress dosing required:
→ discontinue daily hydrocortisone
→ continue stress dosing as needed
→ low-dose ACTH stimulation testing
↓
If with ACTH testing:
Peak cortisol > 500 nmol/L: HPA axis is intact and GC can be discontinued
Peak cortisol < 500 nmol/L: Steroids required at times of stress and illness until normal ACTH response is noted
GC: glucocorticoid; HPA: hypothalamic-pituitary-adrenal; ACTH: adrenocorticotropic hormone.
*If lab norm for morning cortisol is >171 nmol/L, use lab norm.
†If symptomatic despite normal first morning cortisol, continue daily and stress hydrocortisone and contact pediatric endocrinologist.
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growth velocity with rhGH therapy [164], however further
study, including evaluation of final adult height, is required.
Gastrointestinal (GI) events
Consideration can be given to the use of proton pump in-
hibitors (PPIs) for GI protection in GC users at high-risk ofTable 15 Recommendations for the management of AS in chi
1. Stress steroids during periods of physiological stress
Adrenal crisis/critical illness*: Hydrocortisone injection (Solu-Cortef) 100 m
by 25 mg/m2 q 6 hours (max. 25 mg q 6 ho
Surgery*: Hydrocortisone injection (Solu-Cortef) 50–10
(max 25 mg q 6 hours); call endocrinologist
Illness or fever: 20 mg/m2/day hydrocortisone equivalent, d
Fever >38.5°C or vomiting: 30 mg/m2/day hydrocortisone equivalent, d
Unable to tolerate orally: Hydrocortisone must be administered paren
2. ± Daily physiologic dose of hydrocortisone (8–10 mg/m2/day)
3. Patient/family education
– Stress steroid dosing
– Emergency medical contact information in case of illness
4. Information card*
5. Consider medical identification tag
IV: intravenous; IM: intramuscular; BID: twice daily; TID: three times daily; QID: four t
*At a minimum, symptomatic patients require an information card and stress dosin
Reproduced from Ahmet et al., 2011 [91].GI bleeding or peptic ulcers, such as those using NSAIDS,
patients with a history of ulcers or GI bleeding, and those
with serious comorbidities (i.e., advanced cancer) [1].
Cutaneous events: Red striae
Although treatment of red striae is often disappointing,
some success has been noted with topical vitamin Aldren [91]
g/m2 (max. 100 mg) IV/IM stat with saline volume expansion, followed
urs); call endocrinologist on call
0 mg/m2 IV (max 100 mg) pre-operatively, then 25 mg/m2 q 6 hours
on call
ivided BID or TID
ivided TID
terally as Solu-Cortef, 25 mg/m2/dose q 6 hours IV or q 8 hours IM
imes daily; q: every.
g during critical illness and surgery.
Table 16 Recommendations for the management of AS in adults
Medical or surgical stress Examples of stress Recommended GC dose in addition to usual GC dose
Minor Procedure/surgery: • Inguinal hernia repair Hydrocortisone 25 mg or equivalent pre-op
Medical illness: • Mild febrile illness Hydrocortisone 25 mg/day or equivalent*
• Mild-moderate nausea/vomiting
• Gastroenteritis
Moderate Surgery: • Open cholecystectomy Hydrocortisone 50–75 mg/day or equivalent from pre-op until 1–2 days
after procedure*
• Segmental colon resection
• Total joint replacement
• Abdominal hysterectomy
Medical illness: • Significant febrile illness Hydrocortisone 50–75 mg/day or equivalent during illness*
• Severe gastroenteritis




• Surgery involving cardiopulmonary
bypass
Medical illness: • Pancreatitis Hydrocortisone 100–150 mg/day or equivalent during illness*
Critical illness Hydrocortisone 50–100 mg IV q 6–8 hours then taper as clinical status
improves
*If a corticosteroid with a short half-life (e.g., hydrocortisone) is given, then GC dose should be divided into 2–3 doses/day.
Adapted from: Coursin, Wood, 2002 [161] and Salem et al., 1994 [162].
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combination of pulsed dye laser and Thermage (a non-
ablative radiofrequency device) [44]. To help reduce the
risk of striae, patients initiating systemic corticosteroid
therapy should be advised to follow a low-calorie diet.Conclusions
Systemic corticosteroids are widely used to treat a
variety of autoimmune and inflammatory disorders.
Despite the benefits of these agents, their prolonged use
(particularly at high doses) is associated with potentially
serious AEs affecting the musculoskeletal, endocrine,
CV, and central nervous systems as well as the GI tract.
Many of these side effects can be minimized through
careful patient monitoring and implementation of
preventive measures, including the use of lower potency
agents and the lowest effective dose required for
management of the underlying condition.
Patients should be informed about the AEs associated
with systemic corticosteroid use and should be advised
on lifestyle modification strategies that may help reduce
the risk of these events. Patients should also be
instructed to seek medical attention if they experience
signs and symptoms of steroid-related AEs and should
be advised to carry a steroid treatment card that can be
shown to all healthcare professionals involved in their
care and management. Differences in the monitoring
and care of adults versus children should also be noted,particularly in terms of GC-associated complications
related to growth, AS and osteoporosis.
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